<DOC>
	<DOCNO>NCT02665221</DOCNO>
	<brief_summary>The primary purpose single center , randomize , open label study relapse Multiple Sclerosis ( MS ) patient PLEGRIDY ( peginterferon beta-1a ) ass effect Preparation H ( phenylephrine ) Maximum Strength Cream compare topical treatment injection site erythema PLEGRIDY injection .</brief_summary>
	<brief_title>Single Center , Open Label , Study Preparation H Erythema Relapsing MS Patients Treated With PLEGRIDY</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Erythema</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<criteria>A confirmed diagnosis relapse multiple sclerosis , define McDonald criterion . Age 18 70 year old , inclusive , time informed consent . Na√Øve PLEGRIDY less equal 12 month PLEGRIDY therapy . Primary progressive , secondary progressive progressive relapse MS. Concurrent enrollment clinical trial investigational product . Known allergy interferon component PLEGRIDY ( peginterferon beta1a ) . Known allergy phenylephrine , pramoxane component Preparation H. History hypersensitivity intolerance naproxen acetaminophen ( Tylenol ) would preclude use least 1 study . History inadequate response subcutaneous interferon beta therapy . History human immunodeficiency virus , hepatitis C virus antibody current hepatitis B infection . History premalignant malignant disease include solid tumor hematologic malignancy ( except basal cell squamous cell carcinoma skin completely excise consider cure ) . History clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , major disease , determine Investigator . History seizure disorder unexplained blackout . History suicidal ideation episode clinically severe depression ( determined Investigator ) within 3 month prior Day 1 . Serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( e.g. , pneumonia , septicemia ) , discretion Investigator , within 3 month prior Day 1 . History drug alcohol abuse ( define Investigator ) within 6 month prior Day . Active bacterial viral infection . Inability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>erythema</keyword>
</DOC>